PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31215755-0	2019	Safety, Tolerability, and Pharmacokinetics of the beta-Site Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitor Verubecestat (MK-8931) in Healthy Elderly Male and Female Subjects.	verubecestat	128-135	beta-secretase 1	Homo sapiens	50-103	
31423903-2	2019	Abeta is formed by the cleavage of amyloid precursor protein by beta-site amyloid precure protein cleaving enzyme (BACE1) and the BACE1 inhibitor verubecestat was developed to lower the brain levels of Abeta.	verubecestat	146-158	beta-secretase 1	Homo sapiens	115-120	
31423903-2	2019	Abeta is formed by the cleavage of amyloid precursor protein by beta-site amyloid precure protein cleaving enzyme (BACE1) and the BACE1 inhibitor verubecestat was developed to lower the brain levels of Abeta.	verubecestat	146-158	beta-secretase 1	Homo sapiens	130-135	
34825396-1	2022	We report the neuropathological examination of a patient with Alzheimer"s disease (AD) treated for 38 months with low doses of the BACE-1 inhibitor verubecestat.	verubecestat	148-160	beta-secretase 1	Homo sapiens	131-137	
33252075-1	2021	BACKGROUND: We performed exploratory analyses of retinal thickness data from a clinical trial of the AbetaPP cleaving enzyme (BACE) inhibitor verubecestat in patients with Alzheimer"s disease (AD).	verubecestat	142-154	beta-secretase 1	Homo sapiens	126-130	
33252075-9	2021	CONCLUSION: BACE inhibition by verubecestat was not associated with adverse effects on retinal thickness in patients with mild-to-moderate AD.	verubecestat	31-43	beta-secretase 1	Homo sapiens	12-16	
33253354-1	2020	In the phase 3 EPOCH trial (Clinicaltrials.gov; NCT01739348), treatment with the BACE inhibitor verubecestat failed to improve cognition in patients with mild-to-moderate Alzheimer"s disease, but was associated with reduced hippocampal volume after 78 weeks as assessed by MRI.	verubecestat	96-108	beta-secretase 1	Homo sapiens	81-85	
31347728-7	2020	In this review, we aim to discuss the most promising classes of BACE1 inhibitors with a description and analysis of their pharmacodynamic and pharmacokinetic parameters, with more focus on the lead drug candidates that reached late stages of clinical trials, such as MK8931, AZD-3293, JNJ-54861911, E2609, and CNP520.	verubecestat	267-273	beta-secretase 1	Homo sapiens	64-69	
29481097-0	2018	A Next Generation Synthesis of BACE1 Inhibitor Verubecestat (MK-8931).	verubecestat	61-68	beta-secretase 1	Homo sapiens	31-36	
30347431-0	2019	Pharmacokinetics and Pharmacodynamics of the BACE1 Inhibitor Verubecestat (MK-8931) in Healthy Japanese Adults: A Randomized, Placebo-Controlled Study.	verubecestat	61-73	beta-secretase 1	Homo sapiens	45-50	
30347431-0	2019	Pharmacokinetics and Pharmacodynamics of the BACE1 Inhibitor Verubecestat (MK-8931) in Healthy Japanese Adults: A Randomized, Placebo-Controlled Study.	verubecestat	75-82	beta-secretase 1	Homo sapiens	45-50	
27807285-0	2016	The BACE1 inhibitor verubecestat (MK-8931) reduces CNS beta-amyloid in animal models and in Alzheimer"s disease patients.	verubecestat	20-32	beta-secretase 1	Homo sapiens	4-9	
27933948-1	2016	Verubecestat 3 (MK-8931), a diaryl amide-substituted 3-imino-1,2,4-thiadiazinane 1,1-dioxide derivative, is a high-affinity beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor currently undergoing Phase 3 clinical evaluation for the treatment of mild to moderate and prodromal Alzheimer"s disease.	verubecestat	16-23	beta-secretase 1	Homo sapiens	124-177	
27933948-1	2016	Verubecestat 3 (MK-8931), a diaryl amide-substituted 3-imino-1,2,4-thiadiazinane 1,1-dioxide derivative, is a high-affinity beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor currently undergoing Phase 3 clinical evaluation for the treatment of mild to moderate and prodromal Alzheimer"s disease.	verubecestat	16-23	beta-secretase 1	Homo sapiens	179-184	
27934506-0	2016	Synthesis of Verubecestat, a BACE1 Inhibitor for the Treatment of Alzheimer"s Disease.	verubecestat	13-25	beta-secretase 1	Homo sapiens	29-34	
27807285-0	2016	The BACE1 inhibitor verubecestat (MK-8931) reduces CNS beta-amyloid in animal models and in Alzheimer"s disease patients.	verubecestat	34-41	beta-secretase 1	Homo sapiens	4-9